Skip to main content
Home > BC Innovations > Strategy

Chronological Index of : Strategy

 Current Issue
  • Table 1: Allied Minds startups based in the life sciences

    Translational Notes: Meeting of the minds Table 1. Allied Minds startups based in the life sciences. Source: Allied Minds Startup Technology concept Products Origin of technology Biotectix LLC Next-generation …

    Published on 9/4/2014
  • Funding forgotten proteins

    A new NIH program is looking to fund understudied members of druggable protein classes by supporting exploratory projects at risk of being passed over because of a lack of preliminary data.

    Published on 9/4/2014
  • Meeting of the minds

    Allied Minds has partnered with Bristol-Myers Squibb to form Allied-Bristol Life Sciences LLC and can now add therapeutics to its portfolio of academia-based startups.

    Published on 9/4/2014
  • Table 1: Comparison of current awards to support nontraditional funding methods

    Translational Notes: Getting researchers off the grant treadmill Table 1. Comparison of current awards to support nontraditional funding methods. Source: NIH NIH Director's Awards National Cancer Institute …

    Published on 8/28/2014
  • Getting researchers off the grant treadmill

    The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier …

    Published on 8/28/2014
  • Industrial strength for Sanford-Burnham

    GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.

    Published on 8/28/2014
  • AstraZeneca taps the Cambridge wellspring

    AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground …

    Published on 8/21/2014
  • Dementia public-private partnerships

    Translational Notes: AD mission in the U.K. Table 1. Dementia public-private partnerships. Selected public-private partnerships focused on dementia research initiated over the past five years. Date Title Companies…

    Published on 7/24/2014
  • Dementia research initiatives in the U.K.

    Translational Notes: AD mission in the U.K. Table 2. Dementia research initiatives in the U.K. Select U.K.-based dementia research initiatives launched during the past year. Alzheimer's Research UK is contributing a …

    Published on 7/24/2014
  • AD mission in the U.K.

    The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly L120 million (US $205 million) from U.K.-based organizations for a series of research initiatives spanning discovery to the …

    Published on 7/24/2014
  • Table 1: Innovation Fund award recipients

    Translational Notes: Partnering in pediatrics Table 1. Innovation Fund award recipients. The Innovation Fund is managed by Cincinnati Children's Center for Technology Commercialization. Source: Cincinnati Children's…

    Published on 7/17/2014
  • Partnering in pediatrics

    Rare pediatric diseases are getting a boost from Alexion Pharmaceuticals, who recently announced a research collaboration with Cincinnati Children's Hospital Medical Center.

    Published on 7/17/2014
  • CQDM: Canada on the brain

    The Quebec Consortium for Drug Discovery and Brain Canada have announced at least C$10 million (US$9.2 million) in funding for a new program to develop tools for pharma partners to accelerate the discovery of …

    Published on 6/12/2014
  • Table 1: Daiichi Sankyo's cardiovascular and endocrine/metabolic disease pipelines

    Translational Notes: Sanford-Burnham goes fourth Table 1. Daiichi Sankyo's cardiovascular and endocrine/metabolic disease pipelines. The therapies that Daiichi Sankyo Co. Ltd. (Tokyo:4568) has in its pipelines to …

    Published on 6/5/2014
  • Go west, FDA

    The FDA's first two centers for regulatory sciences were focused on modernizing methods and building bridges to academia. The agency now is at earlier drug development and has partnered with Stanford and UCSF to create …

    Published on 6/5/2014
  • Sanford-Burnham goes fourth

    The Sanford-Burnham Medical Research Institute has been seeking broader industrial partnerships that tap both its basic research and drug discovery expertise. Its new deal with Daiichi is the most expansive of its four …

    Published on 6/5/2014
  • Figure 1: Slow to venture in New York

    Translational Notes: New York's biotech beginnings Figure 1. Slow to venture in New York. (I) Venture financing in U.S. biotech hubs, 2010-2014. Sum of amount raised in disclosed venture financing in select U.S. …

    Published on 5/29/2014
  • Table 1: Boosting translation in New York academia

    Translational Notes: New York's biotech beginnings Table 1. Boosting translation in New York academia. Select public-private partnerships (PPPs) and charitable donations involving New York City-based organizations …

    Published on 5/29/2014
  • A conversation with Aled Edwards

    As the Structural Genomics Consortium enters its second decade, SciBX spoke with Aled Edwards about how the open-access business model has evolved globally and the organization's plans to engage clinician scientists and…

    Published on 5/29/2014
  • New York's biotech beginnings

    New York has long been a producer of top science but has struggled to retain and develop its own innovations. Now, with a flurry of activities aiming to establish it as a biotech hub, New York's next task is to persuade…

    Published on 5/29/2014
  • Antibiotic team building

    NIAID has awarded a 5-year, $26 million grant for antibiotic development that brings together researchers from Rutgers University, Rockefeller University and Cubist. The goal is to take discovery-stage programs through …

    Published on 5/22/2014
  • Temple building

    Temple University has teamed up with MorphoSys to bring industry-quality antibody discovery capabilities in-house. The partnership complements the university's medicinal chemistry expertise while expanding the company's…

    Published on 5/8/2014
  • Scripps looks outward

    The Scripps Research Institute has formed a separate corporation called Scripps Advance that will house assets and IP related to discrete early stage research projects. Johnson & Johnson's California Innovation Center …

    Published on 5/1/2014
  • Stem cell disarray

    The NIH is rethinking its strategy for translating stem cell therapies. Stakeholders hope the message will be that the NIH should focus less on drug development and more on standardizing procedures and protocols.

    Published on 5/1/2014
  • Table 1: Clinical bromodomains

    Translational Notes: Expanding into new (bromo)domains Table 1. Clinical bromodomains. At least six companies have compounds that inhibit bromodomains, including the bromodomain containing 2 (BRD2), BRD3 and BRD4 …

    Published on 4/17/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993